Leptin modulates dose-dependently the metabolic and cytolytic activities of NK-92 cells

Journal of Cellular Physiology

Volumn 228, Issue 6, 2013, Pages 1202-1209

  Lamas, Bruno ^a   Goncalves Mendes, Nicolas ^a   Nachat Kappes, Rachida ^a   Rossary, Adrien ^a   Caldefie Chezet, Florence ^a   Vasson, Marie Paule ^a,b   Farges, Marie Chantal ^a  

^a INRA and University of Auvergne   (France)

^b CENTRE JEAN PERRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; GRANZYME B; IONOMYCIN; LEPTIN; MESSENGER RNA; PERFORIN; RESAZURIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CELL CULTURE; CELL CYCLE; CELL DEATH; CELL FUNCTION; CELL METABOLISM; CELL STIMULATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LYMPHOMA CELL LINE; NATURAL KILLER CELL; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GREEN FLUORESCENT PROTEINS; HUMANS; INDICATORS AND REAGENTS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; IONOMYCIN; K562 CELLS; KILLER CELLS, NATURAL; LEPTIN; MCF-7 CELLS; OXAZINES; PERFORIN; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, LEPTIN; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; UP-REGULATION; XANTHENES;

EID: 84874220772     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24273     Document Type: Article

References (53)

1. Abarca-Rojano E, Muniz-Hernandez S, Moreno-Altamirano MM, Mondragon-Flores R, Enriquez-Rincon F, Sanchez-Garcia FJ. 2009. Re-organization of mitochondria at the NK cell immune synapse. Immunol Lett 122:18-25.
2. Allegra S, Deleine C, Michael-Jubely R, Gryson C, Boirie Y, Kantakamalakul W, Vasson MP. 2006. Implementation of the EGFP-K562 flow cytometric NK test: Determination of NK cytotoxic activity in healthy elderly volunteers before and after feeding. Cytometry A 69:992-998.
3. Barr VA, Lane K, Taylor SI. 1999. Subcellular localization and internalization of the four human leptin receptor isoforms. J Biol Chem 274:21416-21424.
4. Belouzard S, Delcroix D, Rouille Y. 2004. Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway. J Biol Chem 279:28499-28508.
5. Bhattacharya K, Samanta SK, Tripathi R, Mallick A, Chandra S, Pal BC, Shaha C, Mandal C. 2010. Apoptotic effects of mahanine on human leukemic cells are mediated through crosstalk between Apo-1/Fas signaling and the bid protein and via mitochondrial pathways. Biochem Pharmacol 79:361-372.
6. Calle EE, Kaaks R. 2004. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591.
7. Chandra RK. 1980. Cell-mediated immunity in genetically obese C57BL/6J ob/ob mice. Am J Clin Nutr 33:13-16.
8. Conde J, Scotece M, Gomez R, Gomez-Reino JJ, Lago F, Gualillo O. 2010. At the crossroad between immunity and metabolism: Focus on leptin. Expert Rev Clin Immunol 6:801-808.
9. Cullen SP, Martin SJ. 2008. Mechanisms of granule-dependent killing. Cell Death Differ 15:251-262.
10. Czekanska EM. 2011. Assessment of cell proliferation with resazurin-based fluorescent dye. Methods Mol Biol 740:27-32.
11. Danforth DN, Zhu Y. 2005. Conversion of Fas-resistant to Fas-sensitive MCF-7 breast cancer cells by the synergistic interaction of interferon-gamma and all-trans retinoic acid. Breast Cancer Res Treat 94:81-91.
12. El Guerrab A, Zegrour R, Nemlin CC, Vigier F, Cayre A, Penault-Llorca F, Rossignol F, Bignon YJ. 2011. Differential impact of EGFR-targeted therapies on hypoxia responses: Implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS ONE 6:e25080.
13. Fantuzzi G, Faggioni R. 2000. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 68:437-446.
14. Fernandez-Riejos P, Najib S, Santos-Alvarez J, Martin-Romero C, Perez-Perez A, Gonzalez-Yanes C, Sanchez-Margalet V. 2010. Role of leptin in the activation of immune cells. Mediators Inflamm 2010:568343.
15. Grossmann ME, Ray A, Nkhata KJ, Malakhov DA, Rogozina OP, Dogan S, Cleary MP. 2010. Obesity and breast cancer: Status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev 29:641-653.
16. Ikeda H, Old LJ, Schreiber RD. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95-109.
17. Jang JY, Jeon YK, Choi Y, Kim CW. 2010. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression. Mol Cancer 9:262.
18. Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, Vasson MP. 2009. Involvement of adiponectin and leptin in breast cancer: Clinical and in vitro studies. Endocr Relat Cancer 16:1197-1210.
19. Jarde T, Perrier S, Vasson MP, Caldefie-Chezet F. 2011. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 47:33-43.
20. Kanda T, Takahashi T, Kudo S, Takeda T, Tsugawa H, Takekoshi N. 2004. Leptin deficiency enhances myocardial necrosis and lethality in a murine model of viral myocarditis. Life Sci 75:1435-1447.
21. Kantakamalakul W, Jaroenpool J, Pattanapanyasat K. 2003. A novel enhanced green fluorescent protein (EGFP)-K562 flow cytometric method for measuring natural killer (NK) cell cytotoxic activity. J Immunol Methods 272:189-197.
22. Kim MJ, Kim HB, Bae JH, Lee JW, Park SJ, Kim DW, Park SI, Kang CD, Kim SH. 2009. Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway. Biochem Pharmacol 78:573-582.
23. Lanier LL. 2005. NK cell recognition. Annu Rev Immunol 23:225-274.
24. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, Diehl AM. 1998. Leptin regulates proinflammatory immune responses. FASEB J 12:57-65.
25. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. 1998. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394:897-901.
26. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM. 1995. Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1:1155-1161.
27. Magnani E, Bettini E. 2000. Resazurin detection of energy metabolism changes in serum-starved PC12 cells and of neuroprotective agent effect. Brain Res Brain Res Protoc 5:266-272.
28. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, Charaffe-Jaufret E, Birnbaum D, Moretta A, Olive D. 2011. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res 71:6621-6632.
29. Matarese G, Moschos S, Mantzoros CS. 2005. Leptin in immunology. J Immunol 174:3137-3142.
30. Merlin E, Goncalves-Mendes N, Hannani D, de la Torre A, Farges MC, Laroye H, Demeocq F, Kanold J, Vasson MP. 2011. Extracorporeal photochemotherapy induces arginase 1 in patients with graft versus host disease. Transpl Immunol 24:100-106.
31. Nave H, Mueller G, Siegmund B, Jacobs R, Stroh T, Schueler U, Hopfe M, Behrendt P, Buchenauer T, Pabst R, Brabant G. 2008. Resistance of Janus kinase-2 dependent leptin signaling in natural killer (NK) cells: A novel mechanism of NK cell dysfunction in diet-induced obesity. Endocrinology 149:3370-3378.
32. Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP. 2009. Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep 21:1611-1619.
33. O'Brien J, Wilson I, Orton T, Pognan F. 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267:5421-5426.
34. Rahman M, Pumphrey JG, Lipkowitz S. 2009. The TRAIL to targeted therapy of breast cancer. Adv Cancer Res 103:43-73.
35. Ray A, Nkhata KJ, Cleary MP. 2007. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol 30:1499-1509.
36. Renehan AG. 2010. Obesity and cancer in Asia-Pacific populations. Lancet Oncol 11:704-705.
37. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. 2000. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 60:5673-5680.
38. Saxena NK, Vertino PM, Anania FA, Sharma D. 2007. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J Biol Chem 282:13316-13325.
39. Schoenborn JR, Wilson CB. 2007. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41-101.
40. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. 2005. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 42:495-499.
41. Screpanti V, Wallin RP, Ljunggren HG, Grandien A. 2001. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol 167:2068-2073.
42. Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193:661-670.
43. Street SE, Cretney E, Smyth MJ. 2001. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97:192-197.
44. Tian Z, Sun R, Wei H, Gao B. 2002. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: Leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun 298:297-302.
45. Tilg H, Moschen AR. 2006. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772-783.
46. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. 2001. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10:535-544.
47. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331:44-49.
48. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. 2008. Functions of natural killer cells. Nat Immunol 9:503-510.
49. Vona-Davis L, Rose DP. 2007. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14:189-206.
50. Wang R, Jaw JJ, Stutzman NC, Zou Z, Sun PD. 2011. Natural killer cell-produced IFN-gamma and TNF-alpha induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol 91:299-309.
51. Wrann CD, Laue T, Hubner L, Kuhlmann S, Jacobs R, Goudeva L, Nave H. 2012. Short-term and long-term leptin exposure differentially affect human natural killer cell immune functions. Am J Physiol Endocrinol Metab 302:E108-E116.
52. Yu W, Israel K, Liao QY, Aldaz CM, Sanders BG, Kline K. 1999. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: Role for Mr 43, 000 Fas in VES-triggered apoptosis. Cancer Res 59:953-961.
53. Zhao Y, Sun R, You L, Gao C, Tian Z. 2003. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun 300:247-252.